VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 128 filers reported holding VERVE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $48,136 | -77.4% | 9,864 | -38.6% | 0.01% | -74.1% |
| Q1 2024 | $213,423 | +73.7% | 16,071 | +82.3% | 0.03% | +12.5% |
| Q4 2023 | $122,881 | +464.7% | 8,815 | +437.2% | 0.02% | +300.0% |
| Q3 2023 | $21,760 | +42.9% | 1,641 | +102.1% | 0.01% | +20.0% |
| Q2 2023 | $15,225 | +26.4% | 812 | -2.8% | 0.01% | +25.0% |
| Q1 2023 | $12,041 | -0.6% | 835 | +33.4% | 0.00% | -20.0% |
| Q4 2022 | $12,113 | -36.2% | 626 | +11.6% | 0.01% | -37.5% |
| Q3 2022 | $19,000 | – | 561 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |